

DAFTAR PUSTAKA

1. Sadock BJ, Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Vol. 2015. Wolters Kluwer Philadelphia, PA; 2015.
2. American Psychiatric Association D, Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. Vol. 5. American psychiatric association Washington, DC; 2013.
3. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. *Schizophr Bull.* 2018;44(6):1195–203.
4. Kemenkes RI. Hasil utama RISKESDAS 2018. 2018;
5. Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. *World psychiatry.* 2019;18(2):146–61.
6. Fischer BA, Buchanan RW. Schizophrenia in adults: Epidemiology and pathogenesis. UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA. 2017;
7. Sinkeviciute I, Begemann M, Prikken M, Oranje B, Johnsen E, Lei WU, et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. *NPJ Schizophr.* 2018;4(1):22.
8. Fujino H, Sumiyoshi C, Yasuda Y, Yamamori H, Fujimoto M, Fukunaga M,

- et al. Estimated cognitive decline in patients with schizophrenia: A multicenter study. *Psychiatry Clin Neurosci*. 2017 May;71(5):294–300.
9. McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. *Mol Psychiatry* [Internet]. 2023; Available from: <https://doi.org/10.1038/s41380-023-01949-9>
 10. Kim BJ, Liu L, Cheung C, Ahn J. Effects of cognitive impairment and functional limitation on depressive symptoms among community-dwelling older Korean immigrants in the US. *PLoS One*. 2018;13(3):e0193092.
 11. Martínez AL, Brea J, Rico S, de Los Frailes MT, Loza MI. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments. *Int J Mol Sci*. 2021 Sep;22(18).
 12. Šagud M, Mihaljević-Peleš A, Mück-Šeler D, Pivac N, Vuksan-Ćusa B, Brataljenović T, et al. Smoking and schizophrenia. *Psychiatr Danub*. 2009;21(3):371–5.
 13. Ding JB, Hu K. Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications. *Schizophr Res Treatment*. 2021;2021:7698030.
 14. Dondé C, Brunelin J, Mondino M, Cellard C, Rolland B, Haesebaert F. The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review. *Neurosci Biobehav Rev*. 2020;118:121–33.

15. Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. *Neuropsychol Rev.* 2007;17:259–73.
16. Güleç G, Akarsu O, Mutlu Sahin F, Essizoglu A, Köşger F, Sezer E, et al. The effect of chronic cigarette use on cognitive function. *Turk Psikiyatr Derg.* 2018;29(3).
17. Coustals N, Martelli C, Brunet-Lecomte M, Petillion A, Romeo B, Benyamina A. Chronic smoking and cognition in patients with schizophrenia: A meta-analysis. *Schizophr Res.* 2020 Aug;222:113–21.
18. Wei S, Wang D, Wei G, Wang J, Zhou H, Xu H, et al. Association of cigarette smoking with cognitive impairment in male patients with chronic schizophrenia. *Psychopharmacology (Berl).* 2020;237:3409–16.
19. Wang Y-Y, Wang S, Zheng W, Zhong B-L, Ng CH, Ungvari GS, et al. Cognitive functions in smoking and non-smoking patients with schizophrenia: A systematic review and meta-analysis of comparative studies. *Psychiatry Res.* 2019;272:155–63.
20. Stahl SM. *Essential psychopharmacology: Neuroscientific basis and practical applications.* Cambridge university press; 2000.
21. Kim M, Park J-M. Factors affecting cognitive function according to gender in community-dwelling elderly individuals. *Epidemiol Health.* 2017;39.
22. Mihaljević-Peleš A, Bajš Janović M, Šagud M, Živković M, Janović Š, Jevtović S. Cognitive deficit in schizophrenia: an overview. *Psychiatr*

- Danub. 2019;31(suppl 2):139–42.
23. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, et al. NMDA receptors, cognition and schizophrenia—testing the validity of the NMDA receptor hypofunction hypothesis. *Neuropharmacology*. 2012;62(3):1401–12.
 24. Wixted JT, Thompson-Schill SL. *Stevens' Handbook of Experimental Psychology and Cognitive Neuroscience, Language and Thought*. Vol. 3. John Wiley & Sons; 2018.
 25. Quigley H, MacCabe JH. The relationship between nicotine and psychosis. *Ther Adv Psychopharmacol*. 2019;9:2045125319859969.
 26. Harvey PD, Isner EC. Cognition, social cognition, and functional capacity in early-onset schizophrenia. *Child Adolesc Psychiatr Clin*. 2020;29(1):171–82.
 27. Huang Y-C, Lee Y, Lee C-Y, Lin P-Y, Hung C-F, Lee S-Y, et al. Defining cognitive and functional profiles in schizophrenia and affective disorders. *BMC Psychiatry*. 2020;20(1):1–9.
 28. Besson M, Forget B. Cognitive dysfunction, affective states, and vulnerability to nicotine addiction: A multifactorial perspective. *Front psychiatry*. 2016;7:160.
 29. Eşsizoğlu A, Köşger F, Akarsu FÖ, Özaydin Ö, Güleç G. Theory of mind and selective attention, response inhibition, cognitive flexibility in patients

- with schizophrenia. *Arch Neuropsychiatry*. 2017;54(2):162.
30. Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. *Nov antischizophrenia Treat*. 2012;11–37.
 31. Arnsten AFT, Girgis RR, Gray DL, Mailman RB. Novel dopamine therapeutics for cognitive deficits in schizophrenia. *Biol Psychiatry*. 2017;81(1):67–77.
 32. Simón Expósito M, Felipe Castaño E. Cognitive insight, neurocognition and life skills in patients with schizophrenia. *Psicothema*. 2018;
 33. Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, et al. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. *Schizophr Res*. 2017;190:172–9.
 34. Silberstein J, Harvey PD. Cognition, social cognition, and Self-assessment in schizophrenia: prediction of different elements of everyday functional outcomes. *CNS Spectr*. 2019;24(1):88–93.
 35. Abi Chahine J, Rammal S, Fares Y, Abou Abbas L. Trail making test: Normative data for the Lebanese adult population. *Clin Neuropsychol*. 2020;34(sup1):29–42.
 36. Dahmen J, Cook D, Fellows R, Schmitter-Edgecombe M. An analysis of a digital variant of the Trail Making Test using machine learning techniques. *Technol Heal Care*. 2017;25(2):251–64.

37. Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. *Nat Protoc.* 2006;1(5):2277–81.
38. Prayitno GE, Siaputra IB, Lasmono HK. Validasi alat ukur irrational procrastination scale (IPS). *Calyptra.* 2013;2(1):1–7.
39. Aydın E, Ülgen MC, Tabo A, Balaban ÖD, Yeşilyurt S, Yumrukçal H. Executive function and genetic loading in nonpsychotic relatives of schizophrenia patients. *Psychiatry Res.* 2017;248:105–10.
40. Gignac GE, Reynolds MR, Kovacs K. Digit Span subscale scores may be insufficiently reliable for clinical interpretation: distinguishing between stratified coefficient alpha and omega hierarchical. *Assessment.* 2019;26(8):1554–63.
41. Woods DL, Kishiyama MM, Yund EW, Herron TJ, Edwards B, Poliva O, et al. Improving digit span assessment of short-term verbal memory. *J Clin Exp Neuropsychol.* 2011;33(1):101–11.
42. Gass CS, Patten B, Penate A, Rhodes A. The Cognitive Difficulties Scale (CDS): Psychometric characteristics in a clinical referral sample. *J Int Neuropsychol Soc.* 2021;27(4):351–64.
43. Karilampi U. Neurocognition in schizophrenia spectrum disorders. Department of Psychology; Psykologiska institutionen; 2011.
44. Etnier JL, Wideman L, Labban JD, Piepmeyer AT, Pendleton DM, Dvorak KK, et al. The effects of acute exercise on memory and brain-derived

- neurotrophic factor (BDNF). *J Sport Exerc Psychol*. 2016;38(4):331–40.
45. de Sousa Magalhães S, Fernandes Malloy-Diniz L, Cavalheiro Hamdan A. Validity convergent and reliability test-retest of the rey auditory verbal learning test. *Clin Neuropsychiatry*. 2012;9(3).
46. Purba VT. Hubungan Tingkat Kecemasan dengan Perilaku Merokok pada Mahasiswa Fakultas Hukum Kelas Reguler Universitas HKBP Nommensen Medan Tahun Ajaran 2016/2017. 2017;
47. Fagerström K, Russ C, Yu C-R, Yunis C, Foulds J. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. *Nicotine Tob Res*. 2012;14(12):1467–73.
48. Mushtaq N, Beebe LA. A review of the validity and reliability of smokeless tobacco dependence measures. *Addict Behav*. 2012;37(4):361–6.
49. Mazzone P, Tierney W, Hossain M, Puvenna V, Janigro D, Cucullo L. Pathophysiological impact of cigarette smoke exposure on the cerebrovascular system with a focus on the blood-brain barrier: expanding the awareness of smoking toxicity in an underappreciated area. *Int J Environ Res Public Health*. 2010;7(12):4111–26.
50. Wagner S, Helmreich I, Dahmen N, Lieb K, Tadić A. Reliability of Three Alternate Forms of the Trail Making Tests A and B. *Arch Clin Neuropsychol* [Internet]. 2011 Jun 1;26(4):314–21. Available from: <https://doi.org/10.1093/arclin/acr024>

51. Alhowail A. Molecular insights into the benefits of nicotine on memory and cognition (Review). *Mol Med Rep*. 2021 Jun;23(6).
52. Mongan D, Ramesar M, Föcking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment. *Early Interv Psychiatry*. 2020;14(4):385–97.
53. Na K-S, Jung H-Y, Kim Y-K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. *Prog Neuro-Psychopharmacology Biol Psychiatry*. 2014;48:277–86.
54. Mexal S, Frank M, Berger R, Adams CE, Ross RG, Freedman R, et al. Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. *Mol Brain Res*. 2005;139(2):317–32.
55. Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. *J Neuroinflammation*. 2014;11(1):1–12.
56. Zhang Y, Shi H, Yang G, Yang Y, Li W, Song M, et al. Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia. *Transl Psychiatry* [Internet]. 2021;11(1):595. Available from: <https://doi.org/10.1038/s41398-021-01688-x>
57. Stone TW. Does kynurenic acid act on nicotinic receptors? An assessment

- of the evidence. *J Neurochem*. 2020 Mar;152(6):627–49.
58. Isuru A, Rajasuriya M. Tobacco smoking and schizophrenia: re-examining the evidence. *BJPsych Adv* [Internet]. 2019/06/04. 2019;25(6):363–72. Available from: <https://www.cambridge.org/core/article/tobacco-smoking-and-schizophrenia-reexamining-the-evidence/F5F0F1E56D6F1B9D2188B1762E0ADE60>
59. Evensen S, Wisløff T, Lystad JU, Bull H, Ueland T, Falkum E. Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers. *Schizophr Bull*. 2016 Mar;42(2):476–83.
60. Holm M, Taipale H, Tanskanen A, Tiihonen J, Mitterdorfer-Rutz E. Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. *Acta Psychiatr Scand* [Internet]. 2021 Jan 1;143(1):61–71. Available from: <https://doi.org/10.1111/acps.13254>
61. Hakulinen C, McGrath JJ, Timmerman A, Skipper N, Mortensen PB, Pedersen CB, et al. The association between early-onset schizophrenia with employment, income, education, and cohabitation status: nationwide study with 35 years of follow-up. *Soc Psychiatry Psychiatr Epidemiol*. 2019 Nov;54(11):1343–51.
62. Midin M, Razali R, Zamzam R, Fernandez A, Hum LC, Shah SA, et al. Clinical and cognitive correlates of employment among patients with

- schizophrenia: a cross-sectional study in Malaysia. *Int J Ment Health Syst*. 2011 May;5:14.
63. Talreja BT, Shah S, Kataria L. Cognitive function in schizophrenia and its association with socio-demographics factors. *Ind Psychiatry J*. 2013 Jan;22(1):47–53.
 64. Dickinson D, Iannone VN, Wilk CM, Gold JM. General and specific cognitive deficits in schizophrenia. *Biol Psychiatry*. 2004 Apr;55(8):826–33.
 65. Walker E, Bettes BA, Kain EL, Harvey P. Relationship of gender and marital status with symptomatology in psychotic patients. *J Abnorm Psychol*. 1985 Feb;94(1):42–50.
 66. MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, et al. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. *Front psychiatry*. 2018;9:622.
 67. Stewart SA. The effects of benzodiazepines on cognition. *J Clin Psychiatry*. 2005;66 Suppl 2:9–13.
 68. Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia. Citrome L, editor. *Schizophr Res Treatment [Internet]*. 2016;2016:8213165. Available from: <https://doi.org/10.1155/2016/8213165>
 69. Mezquida G, Savulich G, Atkinson S, Bernardo M, Fernandez-Egea E. S69.

- A CASE STUDY OF CLOZAPINE AND COGNITION: FRIEND OR FOE? *Schizophr Bull* [Internet]. 2018 Apr 1;44(suppl_1):S351–S351. Available from: <https://doi.org/10.1093/schbul/sby018.856>
70. Pomara N, Willoughby LM, Wesnes K, Sidtis JJ. Increased Anticholinergic Challenge-Induced Memory Impairment Associated with the APOE- ϵ 4 Allele in the Elderly: A Controlled Pilot Study. *Neuropsychopharmacology* [Internet]. 2004;29(2):403–9. Available from: <https://doi.org/10.1038/sj.npp.1300305>
71. Vives-Rodriguez A, Robakis D. Chapter 20 - Symptomatic Treatment of Residual Neurological or Psychiatric Disease. In: Weiss KH, Schilsky MBT-WD, editors. Academic Press; 2019. p. 209–15. Available from: <https://www.sciencedirect.com/science/article/pii/B9780128110775000207>
72. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. *Neuropsychiatr Dis Treat*. 2006 Dec;2(4):531–6.
73. Alkan E, Davies G, Evans SL. Cognitive impairment in schizophrenia: relationships with cortical thickness in fronto-temporal regions, and dissociability from symptom severity. *npj Schizophr* [Internet]. 2021;7(1):20. Available from: <https://doi.org/10.1038/s41537-021-00149-0>
74. Lucatch AM, Lowe DJE, Clark RC, Kozak K, George TP. Neurobiological Determinants of Tobacco Smoking in Schizophrenia. *Front psychiatry*. 2018;9:672.
75. Sagud M, Mihaljevic Peles A, Pivac N. Smoking in schizophrenia: recent

- findings about an old problem. *Curr Opin Psychiatry*. 2019 Sep;32(5):402–8.
76. Depp CA, Bowie CR, Mausbach BT, Wolyniec P, Thornquist MH, Luke JR, et al. Current smoking is associated with worse cognitive and adaptive functioning in serious mental illness. *Acta Psychiatr Scand*. 2015 May;131(5):333–41.
77. Ward HB, Beermann A, Nawaz U, Halko MA, Janes AC, Moran L V, et al. Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence [Internet]. Vol. 13, *Frontiers in Psychiatry* . 2022. Available from: <https://www.frontiersin.org/articles/10.3389/fpsyt.2022.804055>
78. Beck AK, Baker AL, Todd J. Smoking in schizophrenia: cognitive impact of nicotine and relationship to smoking motivators. *Schizophr Res Cogn* [Internet]. 2015;2(1):26–32. Available from: <https://www.sciencedirect.com/science/article/pii/S2215001314000286>
79. Moss TG, Sacco KA, Allen TM, Weinberger AH, Vessicchio JC, George TP. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. *Drug Alcohol Depend*. 2009 Sep;104(1–2):94–9.
80. Zhang XY, Chen DC, Xiu MH, Haile CN, Sun H, Lu L, et al. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. *PLoS One*. 2012;7(5):e36563.
81. van der Heijden HS, Schirmbeck F, Kempton MJ, van der Gaag M, Allott K,

- Nelson B, et al. Impact of smoking behavior on cognitive functioning in persons at risk for psychosis and healthy controls: a longitudinal study. *Eur Psychiatry*. 2021;64(1):e60.
82. Wade NE, Baca R, Courtney KE, McCabe CJ, Infante MA, Huestis MA, et al. Preliminary evidence for cannabis and nicotine urinary metabolites as predictors of verbal memory performance and learning among young adults. *J Int Neuropsychol Soc*. 2021;27(6):546–58.
83. Mallet J, Godin O, Dansou Y, Mazer N, Scognamiglio C, Berna F, et al. Current (but not ex) cigarette smoking is associated with worse cognitive performances in schizophrenia: results from the FACE-SZ cohort. *Psychol Med* [Internet]. 2022/09/08. 2022;1–12. Available from: <https://www.cambridge.org/core/article/current-but-not-ex-cigarette-smoking-is-associated-with-worse-cognitive-performances-in-schizophrenia-results-from-the-facesz-cohort/0D1CA9C38A81AB10E0C8B3A771EAC64D>
84. Donny EC, Griffin KM, Shiffman S, Sayette MA. The relationship between cigarette use, nicotine dependence, and craving in laboratory volunteers. *Nicotine Tob Res Off J Soc Res Nicotine Tob*. 2008 May;10(5):934–42.
85. Subedi K, Shrestha A, Bhagat T. Assessment of nicotine dependence among tobacco users visiting outreach programs in Dharan, Nepal: a cross-sectional study. *BMC Public Health* [Internet]. 2021;21(1):1515. Available from: <https://doi.org/10.1186/s12889-021-11535-9>

86. Nadar MS, Hasan AM, Alsaleh M. The negative impact of chronic tobacco smoking on adult neuropsychological function: a cross-sectional study. *BMC Public Health* [Internet]. 2021;21(1):1278. Available from: <https://doi.org/10.1186/s12889-021-11287-6>